MAR 13, 2019 10:46 PM PDT

Combination Immunotherapy Stops Liver Cancer Growth

WRITTEN BY: Nouran Amin

The number of individuals diagnosed with liver cancer is on the rise and current therapies are largely ineffective. However, new preclinical data from the University of California San Diego School of Medicine offers renowned hope. In a study published in Hepatology, a combination immunotherapeutic involving a synthetic double-stranded RNA (dsRNA) polyinosinicpolycytidylic acid (polyIC) with a programmed death-ligand 1 (PD-L1) antibody, was shown to suppress tumor growth in the liver.

"We need to find effective new therapies for this disease. The best drugs in the world only extend a patient's life by an average of three months," said Gen-Sheng Feng, PhD, professor of pathology and molecular biology at UC San Diego and senior author on the paper. "Many immunotherapeutic reagents or protocols are in clinic trials, but very few were based on or justified by solid preclinical data. This study may shift the paradigm in liver cancer treatment, by carefully designing a combination therapy that activates multiple innate and adaptive immune functions within the liver."

In mouse models, the combination of the two reagents effectively inhibited the progression of hepatocellular carcinoma (HCC) and with complete tumor remission and tumor-free survival. The focus of the study was on primary liver cancer, but researchers are also reviewing the effects of the combination immunotherapeutic on metastatic liver cancer and the malignant disease at advanced or terminal stages. Additionally, researchers are examining optimal dosages and are considering other reagent combinations that could be more effective.

"Liver cancer is much more complicated than we thought," says Feng. "We and other researchers found recently that deleting classic oncogenes ironically aggravates liver cancer. The liver has a unique immune-tolerant microenvironment. That's why we haven't been able to develop an effective treatment for liver cancer by blocking oncogenic signaling. Immunotherapy with checkpoint inhibitors, while in many clinical trials worldwide, may have uncertain outcomes due to low or poor response."

Source: University of California of San Diego

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
OCT 12, 2021
Health & Medicine
A New Way of Administering Deep Brain Stimulation May Increase Therapeutic Effect Duration in Parkinson's Disease
OCT 12, 2021
A New Way of Administering Deep Brain Stimulation May Increase Therapeutic Effect Duration in Parkinson's Disease
  Parkinson’s Disease (PD) is a specific type of neurological disorder that can significantly impact a p ...
OCT 21, 2021
Cannabis Sciences
Cannabis as a Prospective Treatment for Fibromyalgia? - Emerging Evidence
OCT 21, 2021
Cannabis as a Prospective Treatment for Fibromyalgia? - Emerging Evidence
Fibromyalgia is a common disease impacting millions of adults in the United States. The condition can be extremely debil ...
NOV 02, 2021
Immunology
Green Tea Isn't an Antioxidant After All (But It's Still Good for You)
NOV 02, 2021
Green Tea Isn't an Antioxidant After All (But It's Still Good for You)
Green tea has long been touted as the elixir of youth—high concentrations of chemicals called polyphenols were bel ...
NOV 19, 2021
Genetics & Genomics
Transcriptomics Method Can Reveal Genes Behind Venom Production
NOV 19, 2021
Transcriptomics Method Can Reveal Genes Behind Venom Production
Some of our best medications have come from nature. For years, researchers have been studying the properties of differen ...
NOV 19, 2021
Cannabis Sciences
Topical CBD Reverses UV-Induced Changes in Skin
NOV 19, 2021
Topical CBD Reverses UV-Induced Changes in Skin
Results from a new study published in Nature’s Scientific Reports suggest that topical application of cannabidiol ...
NOV 23, 2021
Health & Medicine
No Short Term Effects of THC-positive Breast Milk
NOV 23, 2021
No Short Term Effects of THC-positive Breast Milk
A recent study found that THC does not have short-term negative effects on an early, premature baby’s health. Rese ...
Loading Comments...